Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 19/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528428 | 0.93 | HPSE (0.86) | HPSEMMP2MMP9MMP8MMP13 | |
| SCHEMBL6244183 | 0.92 | HPSE (1.00) | HPSEMMP2MMP9MMP8MMP13 | |
| SCHEMBL21803222 | 0.90 | HPSE (1.00) | HPSE | |
| SCHEMBL6507068 | 0.89 | HPSE (0.94) | HPSEMMP2MMP9MMP8MMP13 | |
| SCHEMBL6529281 | 0.89 | HPSE (0.80) | HPSE | |
| SCHEMBL20515117 | 0.89 | HPSE (0.79) | HPSE | |
| SCHEMBL20515082 | 0.89 | HPSE (0.79) | HPSE | |
| SCHEMBL6530630 | 0.85 | HPSE (0.74) | HPSE | |
| SCHEMBL6244234 | 0.84 | HPSE (1.00) | HPSEMMP2MMP9MMP8MMP13 | |
| SCHEMBL2246214 | 0.84 | HPSE (0.83) | HPSEMMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2005042496-A1 | (BENZIMIDAZOL-2-YL)-PHENYL-BENZYL-AMINE DERIVATIVES AND METHODS FOR INHIBITING HEPARANASE ACTIVITY | IMCLONE SYSTEMS INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | HPSE 2/4885MMP2 69/4885MMP9 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.